JPOST Repositoryapplication/xmlhttps://storage.jpostdb.org/JPST002062/files/Pool%203-207%20Pool%20condiciones-3.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/Pool%203-207%20Pool%20condiciones-3.wiffhttps://storage.jpostdb.org/JPST002062/files/3-%20R4-207-%20SWATH%20Luisa%201-22.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/3-%20R4-207-%20SWATH%20Luisa%201-22.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%206-207%20Pool%20condiciones-6.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%201-207%20Pool%20condiciones-1.wiffhttps://storage.jpostdb.org/JPST002062/files/3-%20R5-207-%20SWATH%20Luisa%201-24.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/Pool%202-207%20Pool%20condiciones-2.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/Pool%206-207%20Pool%20condiciones-6.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/4-%20R4-207-%20SWATH%20Luisa%201-23.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/Pool%204-207%20Pool%20condiciones-4.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%201-207%20Pool%20condiciones-1.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/4-%20R4-207-%20SWATH%20Luisa%201-23.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%205-207%20Pool%20condiciones-5.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/Pool%207-207%20Pool%20condiciones-7.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%202-207%20Pool%20condiciones-2.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%204-207%20Pool%20condiciones-4.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/Pool%205-207%20Pool%20condiciones-5.wiffhttps://storage.jpostdb.org/JPST002062/files/Pool%207-207%20Pool%20condiciones-7.wiff.scanhttps://storage.jpostdb.org/JPST002062/files/3-%20R5-207-%20SWATH%20Luisa%201-24.wiffprimaryOK200ProteomicsDavid EscorsHomo Sapiens (human)https://repository.jpostdb.org/entry/JPST002062NavarrabiomedjPOSTPARK1, NACP, hPD-l, SLEB2, Peptidomics, PARK4, PPP1R145, hSLE1, hPD-1., tamo, PD1, CD279, PD-1PP17, Thymus-Dependent Lymphocytes, human being, PP19, Neoplasms, Benign Neoplasm, T-Lymphocyte, Tumor, Malignant, Human, RPL23, T Lymphocyte, Homo sapiens, resilient, tough, SMN, Smn, 1110025J15Rik, immature T cell, Man, C1orf215, strong, Ly101, 19k, Man (Taxonomy), Malignancy, T-Cells, dSTRAD, T, DmelCG7693, CD279, 4624, Pp17, genetic, Pp18, Neoplasias, T Cells, Pdc1, mature T cell, Pp19, Pig, L17, Lag, LAG, Malignancies, P18, l(3)07551, P19, constitutitional genetic, T Lymphocytes, Thymus Dependent Lymphocytes, Lymphocyte, Cancer, Tumors, Malignant Neoplasm, SLEB2, Modern, familial, l17, lag, RCB2758, Cell, Benign, rpl17a, T-Cell, pd-1, LAP18, Neoplasm, STE20-like/SPAK, T lymphocyte, PD1, PD-1, Lap18, dOSR1, T-cell, Pr22, Drives, distinct, CG7693, Op18, Thymus-Dependent, 60S ribosomal protein L23, Benign Neoplasms, Lymphocytes, rpl23, Cancers, T-lymphocyte, human, Thymus-Dependent Lymphocyte, hPD-1, Malignant Neoplasms, hPD-l, T cell, PR22, hSLE1, OP18, Modern Man, Cells, rpl17, T Cell, inherited genetic, hereditary, Neoplasia, Malignant Neoplasms.falseProteomics in PD1-LAG3 biologyT-cell lines with constitutively active PD-1, LAG-3 pathways or their combination were generated to drive distinct types of T-cell dysfunctionality. Global changes were cross-evaluated among T-cell lines and with the multiomic data from human cancers. Regulated genetic, metabolic and proteomic programmes of strong dysfunctionality in T cells and human cancers were identified at multiple levels.Tue Feb 27 00:00:00 GMT 2024PXD0404089606